Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. (NASDAQ: RTPT) to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.

Leigh syndrome is a severe neurological disorder that typically arises in the first year of life. This condition is characterized by progressive loss of mental and movement abilities (psychomotor regression) and typically results in death within a few years, usually due to respiratory failure.

"We look forward to working with Raptor and the study investigators, using our leading-edge mitochondrial genetic testing capabilities to uncover the important genetic profiling information required for the successful execution of this clinical trial," said Paul Kinnon, President and Chief Executive Officer of Transgenomic. "This is a key example of how Transgenomic works with pharmaceutical companies to employ complementary genetic tests designed to improve clinical diagnoses and outcomes."